All In MedTech

Device Trial Radar · NCT05439161

XEN Glaucoma Gel Stent Versus Trabeculectomy

Multicentric Evaluation of Best Corrected Visual Acuity of the XEN Implant Versus Classic Trabeculectomy in Open Angle Glaucoma Subjects

Last checked: Nov 19, 2026Latest source record: Jun 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 196 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

196

Planned (sponsor's estimate)

Start

Dec 20, 2023

Primary completion

Mar 31, 2026

Study completion Sep 30, 2026

Sponsor

Lead sponsor
Prof. Dr. Herbert ReitsamerAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 30, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicentric evaluation of best corrected visual acuity of the XEN implant versus classic trabeculectomy in open angle glaucoma subjects

Conditions

  • Primary Open Angle Glaucoma
  • Pseudoexfoliation Glaucoma
  • Pigmentary Dispersion Glaucoma

Interventions

  • surgeryDevice

    2 types of filtering glaucoma surgeries (classic trabeculectomy as gold standard, and newer XEN glaucoma microstent) are compared against each other in a prospective multicentric randomized study

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best Corrected Distance Visual Acuity at 1 WeekTime frame: Week 1

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dept. Ophthalmology and Optometry Paracelsus Medical University

    Salzburg, Austria · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.